ConductScience.org, home

Trial · NCT03985943

Outcomes18

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPercentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) PopulationWeek 16The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
PRIMARYPercentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus PopulationWeek 16Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
PRIMARYPercentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT PopulationWeek 16The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
PRIMARYPercentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus PopulationWeek 16Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT PopulationWeek 16The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus PopulationWeek 16Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT PopulationWeek 16The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus PopulationWeek 16Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT PopulationWeek 16The ITT population consisted of all randomized participants.percentage of subjectsNUMBER
SECONDARYPercentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus PopulationWeek 16Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT PopulationWeek 4The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus PopulationWeek 4Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT PopulationWeek 4The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus PopulationWeek 4Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT PopulationWeek 2The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus PopulationWeek 2Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT PopulationWeek 1The ITT population consisted of all randomized participants. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER
SECONDARYPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus PopulationWeek 1Severe pruritus population consisted of all randomized participants with a baseline PP NRS \>=7. Data was planned to be collected and analyzed for Initial Treatment Period.percentage of participantsNUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03985943/outcomes